Fresenius Medical Care AG & Co.Kgaa (FME) NPV
Sell:€43.70Buy:€43.86
€0.17
(0.39%)
Prices delayed by at least 15 minutes
- This stock can be held in a
Stocks and Shares ISASell:€43.70
Buy:€43.86
Change:€0.17
(0.39%)
€0.17
(0.39%)Prices delayed by at least 15 minutes
Sell:€43.70
Buy:€43.86
Change:€0.17
(0.39%)
€0.17
(0.39%)Prices delayed by at least 15 minutes
Director deals
Listed below are trades carried out by directors and other individuals which are required to be notified to the market.
Recent deals
| Date | Name and position (if held) | Deal type | Number of shares dealt | Price per share | Value of trade | Shares remaining |
|---|---|---|---|---|---|---|
| 7 August 2024 | Craig CordolaExecutive Board | Buy Regular purchase transaction | 27,323 | $18.15 | $495,859.06 | 78,896 |
| 23 February 2024 | Craig CordolaExecutive Board | Buy Regular purchase transaction | 31,646 | $19.32 | $611,268.18 | 51,573 |
| 22 February 2024 | Craig CordolaExecutive Board | Buy Regular purchase transaction | 19,927 | $19.37 | $386,018.55 | 19,927 |
| 21 February 2024 | Helen Pring GizaCEO | Buy Regular purchase transaction | 2,861 | $19.22 | $55,000.00 | 16,621 |
5 most significant deals
| Date | Name and position (if held) | Deal type | Number of shares dealt | Price per share | Value of trade | Shares remaining |
|---|---|---|---|---|---|---|
| 23 February 2024 | Craig CordolaExecutive Board | Buy Regular purchase transaction | 31,646 | $19.32 | $611,268.18 | 51,573 |
| 7 August 2024 | Craig CordolaExecutive Board | Buy Regular purchase transaction | 27,323 | $18.15 | $495,859.06 | 78,896 |
| 22 February 2024 | Craig CordolaExecutive Board | Buy Regular purchase transaction | 19,927 | $19.37 | $386,018.55 | 19,927 |
| 21 February 2024 | Helen Pring GizaCEO | Buy Regular purchase transaction | 2,861 | $19.22 | $55,000.00 | 16,621 |
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Director deal information provided by Factset.